

10 February 2025

## INOVIQ ESTABLISHES MEDICAL AND SCIENTIFIC ADVISORY BOARD

- 
- **Medical and Scientific Advisory Board formed to provide expert guidance on INOVIQ's diagnostic and therapeutic programs**
  - **Members include internationally renowned clinical researchers and oncologists with expertise in exosome science, diagnostics, clinical trials and cancer treatment**
- 

INOVIQ Limited (ASX:IIQ) is pleased to announce the establishment of its Medical and Scientific Advisory Board (MSAB). The MSAB will provide world-class research expertise, clinical insight and strategic advice focusing on liquid biopsy diagnostics and targeted therapeutics for cancer. Its guidance will help steer INOVIQ's key development milestones and clinical trials.

The MSAB comprises the following clinical researchers and oncologists:

- **Professor H. Miles Prince AM:** Leading Clinical Haematologist and Oncologist and Professor at both Melbourne and Monash universities. He is an NHMRC Investigator Fellow and has been principal investigator of over 100 clinical trials including targeted therapeutics (CAR-T therapy) for haematological conditions and cancers.
- **Professor Phillip K. Darcy:** Group Leader of the Cancer Immunotherapy Laboratory at the Peter MacCallum Cancer Centre and NHMRC Principal Research Fellow, focusing on novel T cell-based immunotherapy approaches for cancer in preclinical mouse models and clinical translation.
- **Professor Carlos Salomon:** Director of the University of Queensland Centre for Extracellular Vesicle Nanomedicine, Head of the Translational Extracellular Vesicles in Obstetrics and Gynaecology Group and NHMRC Investigator Fellow, specialising in exosome biology and its clinical translation to diagnostics and therapeutics for ovarian cancer and obstetrical syndromes.
- **Dr James McCracken:** Leading Medical Oncologist specialising in breast cancer treatment at Epworth Healthcare and the Peter MacCallum Cancer Centre. His research interests include the field of liquid biopsies for cancer to personalise treatment and minimise toxicity.

Detailed profiles of the MSAB members are provided in the Appendices.

CEO Leearne Hinch said: *"We are thrilled to welcome these high-calibre clinical researchers and oncologists to join our Advisory Board. Their expertise will be invaluable as we advance our next generation exosome diagnostics and therapeutics towards the clinic. We look forward to working with the Advisory Board to guide our programs and deliver much-needed earlier diagnostics and more effective treatments for cancer."*

Chairman David Williams added: *"I am looking forward to this Board adding depth and clinical expertise to our research of products. I encourage shareholders to read the detailed biographies below and the relevance of each to INOVIQ is obvious and exciting."*

Authorised by the Company Secretary, Mark Edwards.

### FURTHER INFORMATION

**Dr Leearne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)

**David Williams**  
Chairman  
E [dwilliams@kidder.com.au](mailto:dwilliams@kidder.com.au)

## ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company pioneering next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit [www.inoviq.com](http://www.inoviq.com).

## PROFESSOR H. MILES PRINCE MBBS (HONS) MD FRACP FRCPA AFRCMA AFRACD FAHMS

Professor Prince AM is an internationally recognised Australian Haematologist and Oncologist and a Professor of Medicine at Melbourne and Monash universities. He manages all types of blood-related conditions including anaemia, blood clotting disorders and all blood-related cancers. He is Professor/Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare and also a Haematologist at the Peter MacCallum Cancer Centre. He also currently serves as Director at the Snowdome Foundation, the International Society of Cutaneous Lymphoma, and the Myeloma Foundation Australia; and, Chairman of the Medical Scientific Advisory Committee to the Myeloma Foundation Australia, and the LymphomaHub.

Professor Prince is actively engaged in stem cell research and the mechanisms of the immune systems' control of blood and cancer growth. He has been involved in numerous clinical trials of new therapies for blood cancers and has been the Principal Investigator of over 100 clinical trials involving myeloma, lymphoma, leukaemia, transplantation and supportive care. He has published over 500 peer-reviewed manuscripts. He has been the Chief Investigator for an NHMRC Program Grant in Cancer Immunology, Victorian Cancer Agency translational grants in Epigenetics, Melbourne Genomics Health Alliance and holds large US and European research grants. He is a Fellow of the Academy of Health & Medical Sciences and in 2014 Miles was appointed a Member of the Order of Australia for distinguished services to medicine particularly in the areas of blood cancer research, patient care and philanthropy leadership.

## PROFESSOR PHILLIP K. DARCY PHD FAHMS

Professor Darcy is an NHMRC L3 Investigator Fellow and Group Leader, of the Cancer Immunotherapy Laboratory, at the Peter MacCallum Cancer Centre. His laboratory focuses on developing novel T cell-based immunotherapy approaches for cancer in preclinical mouse models and translating this into patients. Specifically, he is focused on the development of gene modified mouse and human T cells expressing chimeric antigen receptors (CARs) that can effectively target and eradicate cancer in mice. A Phase I clinical trial leading from this work was recently completed at the Peter MacCallum Cancer Centre in patients with acute myeloid leukaemia which represented a first in Australia using this approach, with another trial using this approach underway in solid cancers. His laboratory is also focused on development of combined immune based therapies for cancer.

His laboratory is involved in developing novel strategies for effectively harnessing the immune system against cancer. The goal of the Darcy laboratory is to develop effective immunotherapies for cancer. There is considerable power in the many billions of circulating blood cells that comprise the immune system. One focus is to turn this disease-fighting capacity against cancer cells by using anti-cancer genes to endow immune cells with the ability to recognize and destroy tumour cells. Studies in the lab are divided into: (1) Strategies to enhance endogenous anti-tumor immunity, (2) Combination therapies, where gene-modified immune cells are combined with reagents to overcome the tumour induced immunosuppressive microenvironment to produce the optimal anti-tumour treatment, (3)

Cell selection, in which the relative anti-tumour effect of different gene-modified immune cells are examined in vivo, and (4) Clinical translation, in which final preparations of genes and cells are made ready for use in clinical trials.

#### **PROFESSOR CARLOS SALOMON BBIOCHEM MCLINMED PHD**

Professor Salomon is the Director of the University of Queensland Centre for Extracellular Vesicle Nanomedicine, Head of the Translational Extracellular Vesicles (EV) in Obstetrics and Gynaecology Group, NHMRC Investigator Fellow and a worldwide authority on EV biomarkers with more than 190 publications. He is an acknowledged key opinion leader on EV/exosomes (rated 3rd worldwide and 1st in Australia for expertise in “Extracellular Vesicles and Exosomes” on Expertscape) and biomarker discovery. He has made a major conceptual contribution to EV biology with diagnostic and therapeutic implications. In the last 10 years, Professor Salomon’s primary research and commercialisation activities have focused on the identification and validation of biomarkers, and development of In Vitro Multivariate Index Assays for clinically relevant complications (including ovarian cancers, and obstetrical syndromes) and their translation into clinical applications.

Prof Salomon’s research is focused on obstetrics and gynaecology, investigating the release of EV by the placenta during gestation, and tumour cells in ovarian cancer progression, and their utility as biomarkers for a wide range of pregnancy complications, and ovarian cancer. The impact of his publications has been: (1) identifying new pathways for fetal-maternal, and cancer communication; and (2) establishing the clinical utility of endogenous nanovesicles as liquid biopsy biomarkers for complications of pregnancy, and ovarian cancer, and their utility as therapeutic agents. Prof Salomon is a pioneer in establishing Quality Management Systems (QMS) in academic laboratories. Research within his program is conducted under ISO standards (ISO 17025) for the isolation and characterisation of EVs, ensuring their clinical utility as biomarkers of disease and therapeutic interventions.

#### **DR JAMES MCCRACKEN MBBS FRACP DipPSYCH MPHA**

Dr McCracken is a leading Medical Oncologist specialising in the management and care of patients with breast and gastrointestinal cancers. He is dedicated to developing a holistic, supportive and team-based approach that places the patient at the centre of a personalised treatment plan. He is a medical oncologist at the Peter MacCallum Cancer Centre and Epworth Healthcare.

Dr McCracken holds a Bachelor of Arts from the University of Melbourne, a Post-Graduate Diploma in Psychology from LaTrobe University and a Masters in Public Health from the University of Sydney. He completed his medical studies at the Australian National University in Canberra and was awarded the AMA Leadership prize in his graduating year. He subsequently undertook his internship and physician training at the Royal Melbourne Hospital and then completed his Medical Oncology training through the Victorian Medical Oncology Training Program at St Vincent's, Northern, Western and Austin Hospitals. In January 2020, he completed a 2-year fellowship in Breast and Gastrointestinal Oncology Clinical Trials at the Olivia Newton-John Cancer Research Institute at the Austin Hospital. Dr McCracken was awarded fellowship of the Royal Australasian College of Physicians in January 2019. He is an active member of the Medical Oncology Group of Australia, the European Society of Medical Oncology, and the American Society of Clinical Oncology. He also serves on the EVIQ breast, upper gastrointestinal and oncology emergencies committees.

Dr McCracken’s work is widely published in academic journals and has presented at both international and national conferences. He is passionate about educating junior doctors, being the founder and course convener of the Melbourne Cancer Course. His areas of interest are breast and gastrointestinal oncology, specifically in ctDNA, genomics and prognostic and predictive biomarkers that seek to personalise treatment and minimise toxicity.